Reduction of exacerbations by the PDE4 inhibitor roflumilast - the importance of defining different subsets of patients with COPD

Por Goehring Udo M, Calverley Peter MA, Rennard Stephen I, Bredenbröker Dirk, Martinez Fernando J
Publicado em 2011-01-01

Reduction of exacerbations by the PDE4 inhibitor roflumilast - the importance of defining different subsets of patients with COPD

Por Rennard, Stephen I, Calverley, Peter MA, Goehring, Udo M, Bredenbröker, Dirk, Martinez, Fernando J
Publicado em 2011

Roflumilast and dyspnea in patients with moderate to very severe chronic obstructive pulmonary disease: a pooled analysis of four clinical trials

Por Rennard, Stephen I, Sun, Shawn X, Tourkodimitris, Stavros, Rowe, Paul, Goehring, Udo M, Bredenbröker, Dirk, Calverley, Peter M A
Publicado em 2014

Reduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPD

Por Grootendorst, Diana C, Gauw, Stefanie A, Verhoosel, Renate M, Sterk, Peter J, Hospers, Jeannette J, Bredenbröker, Dirk, Bethke, Thomas D, Hiemstra, Pieter S, Rabe, Klaus F
Publicado em 2007

Roflumilast attenuates allergen-induced inflammation in mild asthmatic subjects

Por Gauvreau, Gail M, Boulet, Louis-Philippe, Schmid-Wirlitsch, Christine, Côté, Johanne, Duong, MyLinh, Killian, Kieran J, Milot, Joanne, Deschesnes, Francine, Strinich, Tara, Watson, Richard M, Bredenbröker, Dirk, O'Byrne, Paul M
Publicado em 2011